Global Markets for Vaccine Technologies

NEW YORK, Aug. 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Vaccine Technologies
http://www.reportlinker.com/p01595226/Global-Markets-for-Vaccine-Technologies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

A market evaluation for vaccine types/categories for humans and animals, including their respective regional sales, applications, regulatory aspects, market forecasts (through 2017), prospects, innovation and challenges, patent analyses, clinical trials, market leaders and market shares of vaccine sales.

Use this report to:

- Evaluate actual or potential markets for vaccine technologies in terms of specific application sectors and subsectors.
- Assess the current state of human and animal vaccine technologies.
- Learn about acquisitions, mergers, and alliances by companies and global organizations.
- Analyze significant patents and their allotments in each vaccine technology category.
- Know Comprehensive company profiles of major players.

Highlights

- Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.
- Human vaccines led the market in 2011 with sales of $26.4 billion. Sales of human vaccines are expected to increase from $27.6 billion in 2012 to $33.8 billion in 2017, a CAGR of 4.1%.
- Sales of animal vaccines amounted to nearly $5.4 billion in 2011. Growth within the animal vaccine segment is expected to be the highest over the forecast period and is projected to increase from $6.0 billion in 2012 to $9.6 billion in 2017, at a CAGR of 10.1%.

STUDY OBJECTIVES

This BCC study assesses and analyzes advancements in the human and animal vaccine industry. The report discusses the current dynamics of the vaccine market and predicts the future market growth based on factors such as current products, trends in the strategic moves of multinational companies, market share, product pipelines, consumer behavior and the immunization strategies of various governmental and non-governmental organizations. This study also examines the key aspect of health safety for both human and animal vaccination programs. The report presents the present market and its potential for growth, including revenue estimations, product types/categories, market leaders, market shares and factors and drivers influencing the market for human and animal vaccines. In addition, the report summarizes the scientific platforms, innovations, top-selling products and prospective candidates for the present and future market. Vaccine market trends, coverage plans by key vaccine regulatory bodies, patents and health safety concerns are also presented in the report. The opportunities and challenges presented to vaccine manufacturers and government bodies, especially in the developing countries, are discussed within this report. The report presents the sales data of vaccine manufacturing companies and other relevant sources where available. The vaccine market is analyzed by types or categories for human and animal vaccines for the period of 2010 to 2012. In addition, revenue projections are given for 2017. The report also presents data on regional sales of vaccines in North America (the U.S. and Canada), Europe and the emerging markets.

REASONS FOR DOING THIS STUDY

The progress in the vaccine industry from the perspective of usage, coverage, awareness and innovation over the past decade has been noteworthy. The study covers the latest industry developments for human and animal vaccines, including updates on financial, scientific, research and new product developments. Human vaccines offer a solution to improving health worldwide. The report offers companies an analysis that they can use in strategizing their immunization plans going forward. The latest market trends, including mergers/joint ventures, market penetration of large companies in the ever-growing developing markets, research, changing consumer preferences, health and safety awareness and immunization coverage campaigns are driving the vaccine market. These trends are opening up diverse opportunities for manufacturers and scientists to develop innovative and affordable products. This study summarizes these factors for both the human and animal vaccine industries.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This study emphasizes the necessity of vaccines in ensuring the health of both humans and animals. For human vaccines, the focus is on the developing countries where access to vaccines is badly needed. For animals, vaccination is a health safety requirement to ensure the health of animals and to avoid the transference of diseases from animals to humans, for both food producing animals and companion animals. The study offers an overview of the vaccine industry for market participants such as manufacturers, researchers and non-governmental organizations.

SCOPE OF THE STUDY

The report studies the various factors impacting the global market for human and animal vaccines. BCC conducted a market evaluation for vaccine types/categories for humans and animals, including their respective regional sales, applications, regulatory aspects, market forecasts, prospects, innovation and challenges, patent analyses, clinical trials, market leaders and market shares of vaccine sales. The data gathered is for the global markets and statistically validated for the current and forecasted values. Similar techniques were applied for regional data measurements and sales in the respective regions studied. Product details and scientific techniques/platforms are provided based on their commercial and industrial viability. The emerging markets for orphan drugs include India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

METHODOLOGY

BCC employed both primary as well as secondary research methodologies to gather relevant information on the vaccine industry. In order to do that, BCC interviewed industry veterans, including scientists, manufacturers and others as well as conducted relevant searches, including pharmaceutical and vaccine related newsletters, blogs, papers, journals, technical blogs, digests, news feeds, technical articles, company white papers, research papers and other sources. Market projections reflect estimated unit prices, vaccine usage and potential immunization coverage, the present market economy, future application of vaccines and market direction and trends.

INFORMATION SOURCES

BCC researched companies associated with the vaccine industry to acquire data for this study. These companies were mostly manufacturers and end users of vaccines for both humans and animals. BCC contacted industry representatives of vaccine companies, scientists and research teams to gain better insight into the prospects and development of the industry. In addition, BCC consulted scientific papers, research papers and articles, science journal, medical and pharmaceutical papers and journals, company white papers, financial reports, newsletters, company literature, medical and pharmaceutical blogs, product literature, technical articles, periodicals, bulletins, abstracts, regulations, patent files, etc. Pharmaceutical and medical related database searches were also key contributors for the research work




CHAPTER 1 INTRODUCTION 2
STUDY OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
CONTRIBUTIONS OF THE STUDY AND FOR WHOM 3
SCOPE OF THE STUDY 3
METHODOLOGY 3
INFORMATION SOURCES 3
ABOUT THE AUTHOR 4
RELATED BCC RESEARCH REPORTS 4
BCC ONLINE SERVICES 4
DISCLAIMER 5
CHAPTER 2 EXECUTIVE SUMMARY 7
SUMMARY TABLE GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, THROUGH
2017 ($ MILLIONS) 9
SUMMARY FIGURE GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, 2010-2017
($ MILLIONS) 9
CHAPTER 3 OVERVIEW 11
DEFINITION OF A VACCINE 11
DEFINITION OF IMMUNITY 11
ACTIVE 11
PASSIVE 11
HOW VACCINES WORK 12
IMPORTANCE OF VACCINES 12
HISTORY OF VACCINES 12
TABLE 1 HISTORY OF VACCINES 12
TYPES OF VACCINES 14
ATTENUATED (LIVE) VACCINES 14
Types of Attenuated (Live) Vaccines 15
TABLE 2 TYPES OF ATTENUATED (LIVE) VACCINES 15
Advantages and Disadvantages of Attenuated (Live) Vaccines 16
TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES 16
INACTIVATED (KILLED) VACCINES 17
Types of Inactivated (Killed) Vaccines 17
TABLE 4 TYPES OF INACTIVATED (KILLED) VACCINES 17
Advantages and Disadvantages of Inactivated (Killed) Vaccines 18
TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVATED (KILLED) VACCINES 18
TOXOID VACCINES 18
Types of Toxoid Vaccines 19
TABLE 6 TYPES OF TOXOID VACCINES 19
Advantages and Disadvantages of Toxoid Vaccines 19
TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES 19
SUBUNIT VACCINES 20
Types of Subunit Vaccines 20
TABLE 8 TYPES OF SUBUNIT VACCINES 20
Advantages and Disadvantages of Subunit Vaccines 21
TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES 21
CONJUGATE VACCINES 21
Types of Conjugate Vaccines 22
TABLE 10 TYPES OF CONJUGATE VACCINES 22
Advantages and Disadvantages of Conjugate Vaccines 22
TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES 22
RECOMBINANT VECTOR VACCINES 22
Types of Recombinant Vector Vaccines 23
TABLE 12 TYPES OF RECOMBINANT VECTOR VACCINES 23
Advantages and Disadvantages of Recombinant Vector Vaccines 24
TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR
VACCINES 24
DNA VACCINES 24
Types of DNA Vaccines 25
TABLE 14 TYPES OF DNA VACCINES 25
Advantages and Disadvantages of DNA vaccines 25
TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES 25
INFECTIOUS DISEASES PREVENTABLE BY VACCINES 26
HUMAN DISEASES 26
Viral Diseases 26
TABLE 16 VACCINE-PREVENTABLE HUMAN VIRAL DISEASES 27
Bacterial Diseases 28
TABLE 17 VACCINE-PREVENTABLE HUMAN BACTERIAL DISEASES 29
ANIMAL DISEASES 31
Food Producing Animals 32
TABLE 18 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN FOOD PRODUCING
ANIMALS 32
Companion Animals 34
TABLE 19 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN COMPANION
ANIMALS 35
Other Animals 35
TABLE 20 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN OTHER ANIMALS 36
TABLE 21 ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION AND OTHER
ANIMALS 37
CHAPTER 4 REGULATORY ASPECTS 44
REGULATORY ASPECTS 44
TABLE 22 NATIONAL REGULATORY AUTHORITIES OF VACCINES ACROSS REGIONS 44
TABLE 23 REVISIONS TO EXISTING VACCINES, 2010 THROUGH 2012 46
TABLE 24 NEWLY APPROVED VACCINES, 2010 THROUGH 2012 51
TABLE 25 GLOBAL VACCINE RECALLS, 2010 THROUGH 2012 52
REGULATORY DEVELOPMENTS IN VACCINE-PREVENTABLE DISEASE PRODUCTS 53
CHAPTER 5 PREVALENCE 56
INCIDENCE AND IMMUNIZATION OF HUMAN DISEASES 56
REGIONAL DATA 56
TABLE 26 REPORTED INCIDENCE DATA OF HUMAN DISEASES (NO.) 56
TABLE 27 IMMUNIZATION COVERAGE DATA OF HUMAN DISEASES (%) 57
GLOBAL DATA 58
TABLE 28 REPORTED CASES OF VACCINE-PREVENTABLE HUMAN DISEASES
WORLDWIDE, 2010 AND 2011 (NO.) 58
TABLE 29 IMMUNIZATION COVERAGE OF VACCINE-PREVENTABLE HUMAN
DISEASES WORLDWIDE, 2010 AND 2011 (%) 59
GLOBAL IMMUNIZATION UPTAKE DATA 59
TABLE 30 UPTAKE OF NEW AND UNDERUSED VACCINES, 2011 (NO.) 59
GLOBAL DEATHS DUE TO VACCINE-PREVENTABLE DISEASES 60
TABLE 31 DEATHS OF CHILDREN GLOBALLY DUE TO DISEASES PREVENTABLE WITH
VACCINES, 2011 (NO.) 60
TABLE 32 ESTIMATED FUTURE DEATHS AVERTED WITH VACCINES, 2011-2020
(MILLIONS) 61
CHAPTER 6 NEW DEVELOPMENTS 63
NEW DEVELOPMENTS 63
TABLE 33 HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF 2012 64
TABLE 34 ALLIANCES, JOINT VENTURES AND AWARDS FOR THE DEVELOPMENT OF
HUMAN AND ANIMAL VACCINES, 2010-2012 71
NEW COLLABORATIVE TRIALS 72
CHAPTER 7 GLOBAL MARKETS FOR HUMAN AND ANIMAL VACCINES 75
VACCINE MARKET BY CATEGORY 76
MARKET OVERVIEW 76
Recent Developments in Animal Vaccines 77
MARKET REVENUE 77
TABLE 35 GLOBAL SALES OF VACCINES BY CATEGORY, THROUGH 2017 ($
MILLIONS) 78
FIGURE 1 GLOBAL SALES OF VACCINES BY CATEGORY, 2010-2017 ($ MILLIONS) 78
MARKET SHARE 78
TABLE 36 GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011 (%) 79
FIGURE 2 GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011 (%) 79
MARKET BY TYPE 79
MARKET FOR HUMAN VACCINES 79
Market Overview 80
Market Revenue 82
TABLE 37 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2017 ($
MILLIONS) 82
FIGURE 3 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2010-2017 ($
MILLIONS) 82
Market Share 83
TABLE 38 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE,
2011 (%) 83
FIGURE 4 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011
(%) 84
MARKET FOR ANIMAL HEALTH PRODUCTS 84
Market Overview 85
Market Revenue 86
TABLE 39 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2017 ($
MILLIONS) 86
FIGURE 5 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2010-2017 ($
MILLIONS) 86
Market Share 87
TABLE 40 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE,
2011 (%) 87
FIGURE 6 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011
(%) 87
MARKET BY REGION 88
MARKET OVERVIEW 88
Human Vaccines 89
Animal Vaccines 89
MARKET REVENUE 90
TABLE 41 GLOBAL SALES OF VACCINES BY REGION, THROUGH 2017 ($ MILLIONS) 90
FIGURE 7 GLOBAL SALES OF VACCINES BY REGION, 2010-2017 ($ MILLIONS) 90
MARKET SHARE 91
TABLE 42 GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011 (%) 91
FIGURE 8 GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011 (%) 91
MARKET BY APPLICATION 92
HUMAN VACCINES 92
MARKET OVERVIEW 93
MARKET REVENUE 94
TABLE 43 GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, THROUGH 2017
($ MILLIONS) 94
FIGURE 9 GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, 2010-2017 ($
MILLIONS) 95
MARKET SHARE BY APPLICATION 95
TABLE 44 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION,
2011 (%) 96
FIGURE 10 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION,
2011 (%) 96
MARKET SHARES OF TOP-SELLING VACCINES BY APPLICATION 96
TABLE 45 MARKET SHARES OF TOP-SELLING VACCINES BY APPLICATION, 2011 (%) 97
CHAPTER 8 MARKET ANALYSIS OF HUMAN VACCINES 99
MARKET BY TYPE 99
MARKET OVERVIEW 99
MARKET REVENUE 100
TABLE 46 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2017 ($
MILLIONS) 101
FIGURE 11 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2010-2017 ($
MILLIONS) 102
MARKET SHARE 102
TABLE 47 MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%) 102
FIGURE 12 MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%) 103
MARKET BY REGION 103
MARKET OVERVIEW 103
MARKET REVENUE 104
TABLE 48 GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH 2017 ($
MILLIONS) 105
FIGURE 13 GLOBAL SALES OF HUMAN VACCINES BY REGION, 2010-2017 ($
MILLIONS) 105
MARKET SHARE 105
TABLE 49 MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011 (%) 106
FIGURE 14 MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011 (%) 106
Regional Markets for Attenuated (Live) Vaccines 106
Market Overview 107
Market Revenue 108
TABLE 50 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION,
THROUGH 2017 ($ MILLIONS) 108
FIGURE 15 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION,
2010-2017 ($ MILLIONS) 108
Regional Markets for Inactivated Vaccines 109
Market Overview 109
Market Revenue 110
TABLE 51 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION,
THROUGH 2017 ($ MILLIONS) 111
FIGURE 16 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION,
2010-2017 ($ MILLIONS) 111
Regional Markets for Conjugate Vaccines 111
Market Overview 112
Market Revenue 112
TABLE 52 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, THROUGH
2017 ($ MILLIONS) 113
FIGURE 17 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, 2010-2017 ($
MILLIONS) 113
Regional Markets for rDNA/DNA Vaccines 114
Market Overview 114
Market Revenue 115
TABLE 53 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION,
THROUGH 2017 ($ MILLIONS) 115
FIGURE 18 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION,
2010-2017 ($ MILLIONS) 116
Regional Markets for Subunit Vaccines 116
Market Overview 116
Market Revenue 117
TABLE 54 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, THROUGH 2017
($ MILLIONS) 118
FIGURE 19 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, 2010-2017 ($
MILLIONS) 118
Regional Markets for Toxoid Vaccines 118
Market Overview 119
Market Revenue 119
TABLE 55 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, THROUGH 2017 ($
MILLIONS) 119
FIGURE 20 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, 2010-2017 ($
MILLIONS) 120
Regional Markets for Other/Combination Vaccines 120
Market Overview 120
Market Revenue 121
TABLE 56 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION,
THROUGH 2017 ($ MILLIONS) 121
FIGURE 21 global market for other/combination vaccines by region, 2010-2017 ($
MILLIONS) 121
MARKET BY APPLICATION 122
PROPHYLACTIC VACCINES 122
THERAPEUTIC VACCINES 123
TABLE 57 HUMAN VACCINES BASED ON MICROORGANISM 123
MENINGOCOCCAL/PNEUMOCOCCAL DISEASES 124
Meningococcal 124
Pneumococcal Diseases 125
Noninvasive Pneumococcal Diseases 125
Invasive Pneumococcal Diseases 125
Market Revenue 126
TABLE 58 GLOBAL SALES OF HUMAN VACCINES FOR
MENINGOCOCCAL/PNEUMOCOCCAL DISEASES, THROUGH 2017 ($ MILLIONS) 126
FIGURE 22 GLOBAL SALES OF HUMAN VACCINES FOR
MENINGOCOCCAL/PNEUMOCOCCAL DISEASES MARKET, 2010-2017 ($ MILLIONS) 127
INFLUENZA (SEASONAL AND PANDEMIC) DISEASES 128
Market Revenue 129
TABLE 60 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET,
THROUGH 2017 ($ MILLIONS) 130
FIGURE 23 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET,
2010-2017 ($ MILLIONS) 130
Market Share 130
TABLE 61 MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2011 (%) 131
PEDIATRIC POLIO/PERTUSSIS/HIB 131
Market Revenue 133
TABLE 62 GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB
DISEASES MARKET, THROUGH 2017 ($ MILLIONS) 133
FIGURE 24 GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB
DISEASES MARKET, 2010-2017 ($ MILLIONS) 133
Market Share 134
TABLE 63 MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB
VACCINES, 2011 (%) 134
ADULT/ADOLESCENT BOOSTER VACCINES 135
Market Revenue 135
TABLE 64 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER
DISEASES MARKET, THROUGH 2017 ($ MILLIONS) 136
FIGURE 25 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER
DISEASES MARKET, 2010-2017 ($ MILLIONS) 136
Market Share 137
TABLE 65 MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER
VACCINES, 2011 (%) 137
TRAVEL-RELATED AND OTHER ENDEMIC DISEASES 137
Market Revenue 139
TABLE 66 GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER
ENDEMIC DISEASES, THROUGH 2017 ($ MILLIONS) 139
FIGURE 26 GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND
OTHER ENDEMIC DISEASES, 2010-2017 ($ MILLIONS) 140
Market Share 140
TABLE 67 MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND
OTHER ENDEMIC DISEASES, 2011 (%) 141
HPV DISEASE 141
Market Revenue 142
TABLE 68 GLOBAL SALES OF HUMAN VACCINES IN HPV, THROUGH 2017 ($
MILLIONS) 142
FIGURE 27 GLOBAL SALES OF HUMAN VACCINES IN HPV, 2010-2017 ($ MILLIONS) 142
Market Share 143
TABLE 69 MARKET SHARES OF TOP-SELLING HPV VACCINES, 2011 (%) 143
ROTAVIRUS DISEASE 143
Market Revenue 144
TABLE 70 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET, THROUGH
2017 ($ MILLIONS) 144
FIGURE 28 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET,
2010-2017 ($ MILLIONS) 144
Market Share 145
TABLE 71 MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2011 (%) 145
OTHER DISEASES 145
Recent Developments 146
Market Revenue 147
TABLE 72 GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES SEGMENT,
THROUGH 2017 ($ MILLIONS) 147
FIGURE 29 GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES
SEGMENT, 2010-2017 ($ MILLIONS) 147
Market Share 148
TABLE 73 MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES
SEGMENT, 2011 (%) 149
MARKET SHARE OF APPLICATIONS 149
TABLE 74 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION,
2011 (%) 150
FIGURE 30 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION,
2011 (%) 150
INDUSTRY STRUCTURE 150
MARKET LEADERS 151
TABLE 75 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES 151
MARKET SHARES 157
TABLE 76 MANUFACTURER/PROCESSORS' MARKET SHARES OF HUMAN VACCINE
SALES, 2011 (%) 157
FIGURE 31 MANUFACTURERS/PROCESSORS' MARKET SHARES OF HUMAN VACCINE
SALES, 2011 (%) 158
CHAPTER 9 MARKET ANALYSIS OF ANIMAL VACCINES 160
MARKET OVERVIEW 160
MARKET REVENUE 161
TABLE 77 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER,
2010–2012 ($ MILLIONS) 162
FIGURE 32 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER,
2010-2012 ($ MILLIONS) 162
ANIMAL VACCINES 163
MARKET BY TYPE 164
TABLE 78 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2017 ($
MILLIONS) 165
FIGURE 33 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2010-2017 ($
MILLIONS) 165
Vaccines Used in Food Producing Animals 166
Market Overview 166
Market Revenue 167
TABLE 79 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY
REGION, THROUGH 2017 ($ MILLIONS) 167
FIGURE 34 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY
REGION, 2010–2017 ($ MILLIONS) 167
Companion Animal Vaccines 168
Market Overview 168
Market Revenue 169
TABLE 80 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION,
THROUGH 2017 ($ MILLIONS) 169
FIGURE 35 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION,
2010-2017 ($ MILLIONS) 170
Other Animal Vaccines 170
Market Overview 170
Market Revenue 171
TABLE 81 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, THROUGH
2017 ($ MILLIONS) 171
FIGURE 36 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION,
2010-2017 ($ MILLIONS) 171
Market Share 172
TABLE 82 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE,
2011 (%) 172
FIGURE 37 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE,
2011 (%) 172
MARKET BY REGION 173
Market Overview 173
Market Revenue 174
TABLE 83 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2017 ($
MILLIONS) 175
FIGURE 38 GLOBAL SALES OF ANIMAL VACCINES BY REGION, 2010-2017 ($
MILLIONS) 175
Market Share 175
TABLE 84 MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011 (%) 176
FIGURE 39 MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011 (%) 176
INDUSTRY STRUCTURE 176
MARKET LEADERS 176
TABLE 85 LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES 176
MARKET SHARES 178
TABLE 86 MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE
SALES, 2011 (%) 179
FIGURE 40 MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE
SALES, 2011 (%) 180
CHAPTER 10 PATENT ANALYSIS 182
PATENTS BY YEAR 182
TABLE 87 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR,
2010–2012 (NO.) 183
FIGURE 41 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR,
2010-2012 (NO.) 183
PATENTS BY VACCINE TYPE 183
TABLE 88 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE,
2010–2012 (NO.) 184
FIGURE 42 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE,
2010-2012 (NO.) 184
PATENTS BY ASSIGNEE'S COUNTRY 185
ATTENUATED (LIVE) VACCINES 185
TABLE 89 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (NO.) 185
FIGURE 43 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY
ASSIGNEE'S COUNTRY, 2010-2012 (NO.) 185
TABLE 90 SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY
ASSIGNEE'S COUNTRY, 2010-2012 (NUMBER/%) 186
FIGURE 44 SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY
ASSIGNEE'S COUNTRY, 2010-2012 (%) 187
INACTIVATED (KILLED) VACCINES 187
TABLE 91 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (NO.) 188
FIGURE 45 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY
ASSIGNEE'S COUNTRY, 2010-2012 (NO.) 189
TABLE 92 SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (NUMBER/%) 189
FIGURE 46 SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY
ASSIGNEE'S COUNTRY, 2010-2012 (%) 190
TOXOID VACCINES 190
TABLE 93 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S
COUNTRY, 2010–2012 (NO.) 190
FIGURE 47 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S
COUNTRY, 2010-2012 (NO.) 190
TABLE 94 SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S
COUNTRY, 2010–2012 (%) 191
FIGURE 48 SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S
COUNTRY, 2010-2012 (%) 191
SUBUNIT VACCINES 192
TABLE 95 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE'S
COUNTRY, 2010–2012 (NO.) 192
FIGURE 49 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE'S
COUNTRY, 2010-2012 (NO.) 193
TABLE 96 SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S
COUNTRY, 2010–2012 (%) 193
FIGURE 50 SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S
COUNTRY, 2010-2012 (%) 193
CONJUGATE VACCINES 194
TABLE 97 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S
COUNTRY, 2010–2012 (NO.) 194
FIGURE 51 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S
COUNTRY, 2010-2012 (NO.) 195
TABLE 98 SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S
COUNTRY, 2010–2012 (%) 195
FIGURE 52 SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S
COUNTRY, 2010-2012 (%) 196
RECOMBINANT/RDNA/DNA VACCINES 196
TABLE 99 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (NO.) 196
FIGURE 53 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY
ASSIGNEE'S COUNTRY, 2010-2012 (NO.) 197
TABLE 100 SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (%) 198
FIGURE 54 SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY
ASSIGNEE'S COUNTRY, 2010-2012 (%) 199
OTHER/COMBINATION VACCINES 199
TABLE 101 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (NO.) 199
FIGURE 55 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY
ASSIGNEE'S COUNTRY, 2010-2012 (NO.) 200
TABLE 102 SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (%) 201
FIGURE 56 SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY
ASSIGNEE'S COUNTRY, 2010-2012 (%) 202
PATENTS BY COMPANY 202
ATTENUATED (LIVE) VACCINES 202
TABLE 103 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY
COMPANY, 2010–2012 (NO.) 202
FIGURE 57 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY
COMPANY, 2010-2012 (NO.) 203
INACTIVATED (KILLED) VACCINES 204
TABLE 104 U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY
COMPANY, 2010–2012 (NO.) 204
FIGURE 58 U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY
COMPANY, 2010-2012 (NO.) 204
SUBUNIT VACCINES 205
TABLE 105 U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY,
2010–2012 (NO.) 205
FIGURE 59 U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY,
2010-2012 (NO.) 206
CONJUGATE VACCINES 206
TABLE 106 U.S. PATENTS GRANTED ON CONJUGATE VACCINES BY COMPANY,
2010–2012 (NO.) 206FIGURE 60 U.S. PATENTS GRANTED ON CONJUGATE VACCINES BY COMPANY,
2010-2012 (NO.) 207
RECOMBINANT/RDNA/DNA VACCINES 207
TABLE 107 U.S. PATENTS GRANTED ON RECOMBINANT/RDNA/DNA VACCINES BY
COMPANY, 2010–2012 (NO.) 208
FIGURE 61 U.S. PATENTS GRANTED ON RECOMBINANT/RDNA/DNA VACCINES BY
COMPANY, 2010-2012 (NO.) 208
OTHER/COMBINATION VACCINES 209
TABLE 108 U.S. PATENTS GRANTED ON OTHER/COMBINATION VACCINES BY
COMPANY, 2010–2012 (NO.) 209
FIGURE 62 U.S. PATENTS GRANTED ON OTHER/COMBINATION VACCINES BY
COMPANY, 2010-2012 (NO.) 210
PATENTS BY ASSIGNEE 211
ATTENUATED (LIVE) VACCINES 211
TABLE 109 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY
ASSIGNEE TYPE, 2010–2012 (NO.) 212
FIGURE 63 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY
ASSIGNEE TYPE, 2010–2012 (NO.) 212
INACTIVATED (KILLED) VACCINES 212
TABLE 110 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY
ASSIGNEE TYPE, 2010–2012 (NO.) 213
FIGURE 64 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY
ASSIGNEE TYPE, 2010-2012 (NO.) 213
TOXOID VACCINES 213
TABLE 111 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE TYPE,
2010–2012 (NO.) 214
FIGURE 65 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE TYPE,
2010-2012 (NO.) 214
SUBUNIT VACCINES 214
TABLE 112 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE TYPE,
2010–2012 (NO.) 215
FIGURE 66 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE TYPE,
2010-2012 (NO.) 215
CONJUGATE VACCINES 215
TABLE 113 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE TYPE,
2010–2012 (NO.) 216
FIGURE 67 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE TYPE,
2010-2012 (NO.) 216
RECOMBINANT/RDNA/DNA VACCINES 216
TABLE 114 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY
ASSIGNEE TYPE, 2010–2012 (NO.) 217
FIGURE 68 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY
ASSIGNEE TYPE, 2010-2012 (NO.) 217
OTHER/COMBINATION VACCINES 217
TABLE 115 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY
ASSIGNEE TYPE, 2010–2012 (NO.) 218
FIGURE 69 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY
ASSIGNEE TYPE, 2010-2012 (NO.) 218
CHAPTER 11 CURRENT SITUATION 220
ORGANIZATIONS DEDICATED TO GLOBAL IMMUNIZATIONS FOR HUMANS 220
GLOBAL IMMUNIZATION VISION AND STRATEGY (GIVS) 220
GIVS Aims-2006 through 2012 221
GIVS Goals by 2015 or earlier 221
GIVS Strategies 221
GIVS Global Immunization Progress 221
GLOBAL VACCINE ACTION PLAN (GVAP) 222
Six Guiding Principles of GVAP 222
GVAP Goals-2011 through 2020 222
TABLE 116 GVAP GOAL LEVEL TARGETS 223
GVAP Strategic Objectives-2011 through 2010 223
THE GLOBAL ALLIANCE FOR VACCINES AND IMMUNISATION (GAVI) 224
GAVI Potential Forecast-2011 through 2015 224
GAVI Focus 225
GAVI Progress 225
FUNDING AND CHALLENGES 225
UPDATE ON VACCINE-PREVENTABLE DISEASES IN HUMANS 226
WHO PREQUALIFIED MANUFACTURERS OF HUMAN VACCINES 226
TABLE 117 WHO-PREQUALIFIED MANUFACTURERS/SUPPLIERS OF HUMAN
VACCINES, 2012 227
FUTURE VACCINE PRIORITIZATION 227
TABLE 118 VACCINE PRIORITIZATION, 2013-2014 228
CURRENT AND FUTURE (PROPOSED) VACCINE ACHIEVEMENTS AND
CHALLENGES 229
TABLE 119 VACCINE ACHIEVEMENTS AND CHALLENGES THROUGH 2012 230
WHO VACCINE RESEARCH AND PROGRESS 232
TABLE 120 WHO VACCINE RESEARCH AND PROGRESS 232
NEW VACCINE TECHNOLOGIES AND PLATFORMS 232
PROGRESS IN HUMAN VACCINES 233
Peptide Vaccines 233
New Molecular Technique to Control and Develop Malaria Vaccine 233
Hydrogen Peroxide-Based Vaccine Platform 233
PROGRESS IN ANIMAL VACCINES 234
FACTORS AFFECTING THE VACCINE MARKET 234
HIGH PRICES OF NEWER VACCINES 234
LACK OR RESEARCH OPPORTUNITIES 234
WEAK LOCAL HEALTH CENTERS 235
ISSUES WITH MIDDLE INCOME COUNTRIES 235
HURDLES FOR NEW ENTRANTS 235
CURRENT DRIVERS OF THE VACCINE MARKET 235
DRIVERS OF THE MARKET FOR HUMAN VACCINES 235
DRIVERS OF THE MARKET FOR ANIMAL VACCINES 236
ACQUISITIONS/COLLABORATIONS 236
CHAPTER 12 COMPANY PROFILES 239
ABBOTT LABORATORIES 239
ADVAXIS 239
AERAS GLOBAL 240
ALPHAVAX INC. 241
ASTELLAS PHARMA INC. 241
ASTRAZENECA PLC 242
BAXTER INTERNATIONAL INC. 243
BAYER HEALTHCARE ANIMAL HEALTH 244
BHARAT BIOTECH INTERNATIONAL LTD. 245
BIOLOGICAL E. LTD. 246
BIO-MANGUINHOS 246
BIOPROPERTIES 247
BOEHRINGER INGELHEIM GMBH 247
BUL BIO-NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD.
(BB-NCIPD LTD.) 248
CADILA HEALTHCARE LTD. 249
CEVA SANTE ANIMALE 249
CHINA NATIONAL BIOTEC GROUP (CNBG) 251
COLORADO SERUM CO. 252
CRUCELL 252
CSL LTD. 254
ELANCO ANIMAL HEALTH 254
EMERGENT BIOSOLUTIONS INC. 255
FATRO SPA 256
GENVEC INC. 257
GEOVAX 258
GLAXOSMITHKLINE PLC 259
GREEN CROSS CORP. 260
HESKA CORP. 261
IMMUNE SOLUTIONS LTD. 261
INSTITUT PASTEUR DE DAKAR 262
INTERCELL AG 262
JAPAN BCG LABORATORY 264
LG LIFE SCIENCES 264
LOHMANN ANIMAL HEALTH INTERNATIONAL 265
MERCK & CO. INC. 266
MERIAL INC. 267
NIPPON BIOLOGICALS INC. 268
NOVARTIS AG 269
OKAIROS AG 270
PANACEA BIOTEC LTD. 271
PFENEX INC. 271
PFIZER 273
PROFECTUS BIOSCIENCES INC. 274
PT BIO FARMA 275
SANOFI PASTEUR 276
SERUM INSTITUTE OF INDIA LTD. 277
SHANTHA BIOTECHNICS LTD. 278
STATENS SERUM INSTITUT 279
VGX INTERNATIONAL INC. 279
VIRBAC 280
ZOETIS INC. 280
CHAPTER 13 APPENDIX I 284
ABBREVIATIONS 284

LIST OF TABLES

SUMMARY TABLE GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, THROUGH
2017 ($ MILLIONS) 9
TABLE 1 HISTORY OF VACCINES 12
TABLE 2 TYPES OF ATTENUATED (LIVE) VACCINES 15
TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES 16
TABLE 4 TYPES OF INACTIVATED (KILLED) VACCINES 17
TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVATED (KILLED) VACCINES 18
TABLE 6 TYPES OF TOXOID VACCINES 19
TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES 19
TABLE 8 TYPES OF SUBUNIT VACCINES 20
TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES 21
TABLE 10 TYPES OF CONJUGATE VACCINES 22
TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES 22
TABLE 12 TYPES OF RECOMBINANT VECTOR VACCINES 23
TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR
VACCINES 24
TABLE 14 TYPES OF DNA VACCINES 25
TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES 25
TABLE 16 VACCINE-PREVENTABLE HUMAN VIRAL DISEASES 27
TABLE 17 VACCINE-PREVENTABLE HUMAN BACTERIAL DISEASES 29
TABLE 18 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN FOOD PRODUCING
ANIMALS 32
TABLE 19 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN COMPANION
ANIMALS 35
TABLE 20 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN OTHER ANIMALS 36
TABLE 21 ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION AND OTHER
ANIMALS 37
TABLE 22 NATIONAL REGULATORY AUTHORITIES OF VACCINES ACROSS REGIONS 44
TABLE 23 REVISIONS TO EXISTING VACCINES, 2010 THROUGH 2012 46
TABLE 24 NEWLY APPROVED VACCINES, 2010 THROUGH 2012 51
TABLE 25 GLOBAL VACCINE RECALLS, 2010 THROUGH 2012 52
TABLE 26 REPORTED INCIDENCE DATA OF HUMAN DISEASES (NO.) 56
TABLE 27 IMMUNIZATION COVERAGE DATA OF HUMAN DISEASES (%) 57
TABLE 28 REPORTED CASES OF VACCINE-PREVENTABLE HUMAN DISEASES
WORLDWIDE, 2010 AND 2011 (NO.) 58
TABLE 29 IMMUNIZATION COVERAGE OF VACCINE-PREVENTABLE HUMAN DISEASES
WORLDWIDE, 2010 AND 2011 (%) 59
TABLE 30 UPTAKE OF NEW AND UNDERUSED VACCINES, 2011 (NO.) 59
TABLE 31 DEATHS OF CHILDREN GLOBALLY DUE TO DISEASES PREVENTABLE WITH
VACCINES, 2011 (NO.) 60
TABLE 32 ESTIMATED FUTURE DEATHS AVERTED WITH VACCINES, 2011-2020
(MILLIONS) 61
TABLE 33 HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF 2012 64
TABLE 34 ALLIANCES, JOINT VENTURES AND AWARDS FOR THE DEVELOPMENT OF
HUMAN AND ANIMAL VACCINES, 2010-2012 71
TABLE 35 GLOBAL SALES OF VACCINES BY CATEGORY, THROUGH 2017 ($ MILLIONS) 78
TABLE 36 GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011 (%) 79
TABLE 37 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2017 ($
MILLIONS) 82
TABLE 38 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011
(%) 83
TABLE 39 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2017 ($
MILLIONS) 86
TABLE 40 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011
(%) 87
TABLE 41 GLOBAL SALES OF VACCINES BY REGION, THROUGH 2017 ($ MILLIONS) 90
TABLE 42 GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011 (%) 91
TABLE 43 GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, THROUGH 2017 ($
MILLIONS) 94
TABLE 44 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION,
2011 (%) 96
TABLE 45 MARKET SHARES OF TOP-SELLING VACCINES BY APPLICATION, 2011 (%) 97
TABLE 46 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2017 ($
MILLIONS) 101
TABLE 47 MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%) 102
TABLE 48 GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH 2017 ($
MILLIONS) 105
TABLE 49 MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011 (%) 106
TABLE 50 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION,
THROUGH 2017 ($ MILLIONS) 108
TABLE 51 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION,
THROUGH 2017 ($ MILLIONS) 111
TABLE 52 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, THROUGH 2017
($ MILLIONS) 113
TABLE 53 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION,
THROUGH 2017 ($ MILLIONS) 115
TABLE 54 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, THROUGH 2017 ($
MILLIONS) 118
TABLE 55 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, THROUGH 2017 ($
MILLIONS) 119
TABLE 56 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION,
THROUGH 2017 ($ MILLIONS) 121
TABLE 57 HUMAN VACCINES BASED ON MICROORGANISM 123
TABLE 58 GLOBAL SALES OF HUMAN VACCINES FOR
MENINGOCOCCAL/PNEUMOCOCCAL DISEASES, THROUGH 2017 ($ MILLIONS) 126
TABLE 59 MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/PNEUMOCOCCAL
VACCINES, 2011 (%) 127
TABLE 60 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET,
THROUGH 2017 ($ MILLIONS) 130
TABLE 61 MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2011 (%) 131
TABLE 62 GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB
DISEASES MARKET, THROUGH 2017 ($ MILLIONS) 133TABLE 63 MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB
VACCINES, 2011 (%) 134
TABLE 64 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER
DISEASES MARKET, THROUGH 2017 ($ MILLIONS) 136
TABLE 65 MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER
VACCINES, 2011 (%) 137
TABLE 66 GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER
ENDEMIC DISEASES, THROUGH 2017 ($ MILLIONS) 139
TABLE 67 MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND
OTHER ENDEMIC DISEASES, 2011 (%) 141
TABLE 68 GLOBAL SALES OF HUMAN VACCINES IN HPV, THROUGH 2017 ($ MILLIONS) 142
TABLE 69 MARKET SHARES OF TOP-SELLING HPV VACCINES, 2011 (%) 143
TABLE 70 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET, THROUGH
2017 ($ MILLIONS) 144
TABLE 71 MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2011 (%) 145
TABLE 72 GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES SEGMENT,
THROUGH 2017 ($ MILLIONS) 147
TABLE 73 MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES
SEGMENT, 2011 (%) 149
TABLE 74 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION,
2011 (%) 150
TABLE 75 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES 151
TABLE 76 MANUFACTURER/PROCESSORS' MARKET SHARES OF HUMAN VACCINE
SALES, 2011 (%) 157
TABLE 77 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER,
2010–2012 ($ MILLIONS) 162
TABLE 78 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2017 ($
MILLIONS) 165
TABLE 79 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY
REGION, THROUGH 2017 ($ MILLIONS) 167
TABLE 80 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION,
THROUGH 2017 ($ MILLIONS) 169
TABLE 81 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, THROUGH
2017 ($ MILLIONS) 171
TABLE 82 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011
(%) 172
TABLE 83 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2017 ($
MILLIONS) 175
TABLE 84 MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011 (%) 176
TABLE 85 LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES 176
TABLE 86 MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE
SALES, 2011 (%) 179
TABLE 87 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR,
2010–2012 (NO.) 183
TABLE 88 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE,
2010–2012 (NO.) 184
TABLE 89 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (NO.) 185
TABLE 90 SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY
ASSIGNEE'S COUNTRY, 2010-2012 (NUMBER/%) 186
TABLE 91 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (NO.) 188
TABLE 92 SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (NUMBER/%) 189
TABLE 93 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S COUNTRY,
2010–2012 (NO.) 190
TABLE 94 SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S
COUNTRY, 2010–2012 (%) 191
TABLE 95 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE'S
COUNTRY, 2010–2012 (NO.) 192
TABLE 96 SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S
COUNTRY, 2010–2012 (%) 193
TABLE 97 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S
COUNTRY, 2010–2012 (NO.) 194
TABLE 98 SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S
COUNTRY, 2010–2012 (%) 195
TABLE 99 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (NO.) 196
TABLE 100 SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (%) 198
TABLE 101 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (NO.) 199
TABLE 102 SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY
ASSIGNEE'S COUNTRY, 2010–2012 (%) 201
TABLE 103 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY
COMPANY, 2010–2012 (NO.) 202
TABLE 104 U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY
COMPANY, 2010–2012 (NO.) 204
TABLE 105 U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY,
2010–2012 (NO.) 205
TABLE 106 U.S. PATENTS GRANTED ON CONJUGATE VACCINES

To order this report:
Drug_and_Medication Industry: Global Markets for Vaccine Technologies

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker